MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

SPDR S&P Biotech Company Profile (NYSEARCA:XBI)

Consensus Ratings for SPDR S&P Biotech (NYSEARCA:XBI) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for SPDR S&P Biotech (NYSEARCA:XBI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for SPDR S&P Biotech (NYSEARCA:XBI)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for SPDR S&P Biotech (NYSEARCA:XBI)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for SPDR S&P Biotech (NYSEARCA:XBI)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
6/19/2015quarterly$0.440.69%6/19/20156/23/20156/29/2015Tweet This Announcement  Share This Announcement on StockTwits
3/20/2015quarterly$0.250.42%3/20/20153/24/20153/30/2015Tweet This Announcement  Share This Announcement on StockTwits
12/19/2014quarterly$0.491.03%12/19/201412/23/201412/30/2014Tweet This Announcement  Share This Announcement on StockTwits
9/19/2014quarterly$0.561.42%9/19/20149/23/20149/29/2014Tweet This Announcement  Share This Announcement on StockTwits
6/20/2014quarterly$0.621.61%6/20/20146/24/20146/30/2014Tweet This Announcement  Share This Announcement on StockTwits
3/21/2014quarterly$0.330.87%3/21/20143/25/20143/31/2014Tweet This Announcement  Share This Announcement on StockTwits
12/20/2013quarterly$0.040.12%12/20/201312/24/201312/31/2013Tweet This Announcement  Share This Announcement on StockTwits
9/20/2013quarterly$0.090.27%9/20/20139/24/20139/30/2013Tweet This Announcement  Share This Announcement on StockTwits
3/15/2013quarterly$0.040.18%3/15/20133/19/20133/25/2013Tweet This Announcement  Share This Announcement on StockTwits
12/21/2012quarterly$0.200.89%12/21/201212/26/20121/4/2013Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for SPDR S&P Biotech (NYSEARCA:XBI)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for SPDR S&P Biotech (NYSEARCA:XBI)
DateHeadline
06/26/16 06:08 PMLook back at pharma news to June 24 - The Pharma Letter (registration)
06/24/16 07:19 PMBrexit means little for biotech stocks, analyst says - MarketWatch
06/23/16 08:08 PMHealthcare and Biotech Gain in an Otherwise Negative Market
06/22/16 07:18 PMTraders Get It Right (Sort Of) With Leveraged Biotech ETFs - Benzinga
06/22/16 01:07 PMTraders Get It Right (Sort Of) With Leveraged Biotech ETFs -
06/21/16 06:47 PMUnderstanding the Sales Potential of United Therapeutics' Orenitram - Market Realist
06/21/16 06:47 PMBiotech Bloodbath: Ditch XBI, IBB for Now - Investorplace.com
06/20/16 08:41 AMFinance: Runts rally amid mixed earnings season
06/18/16 04:52 AMCelgene Announces an Additional $3 Billion Share Repurchase - Market Realist
06/17/16 07:04 PMFriday's ETF Movers: OIH, XBI
06/16/16 07:31 PMWhy Does XBI's Loss Continue to Widen? - Market Realist
06/15/16 07:11 PMBiotech: It's the Election, Silly - Barron's (blog)
06/15/16 07:11 PMNoteworthy ETF Inflows: XBI, ACAD, ANAC, MDVN - Nasdaq
06/15/16 10:50 AMBiotech: It's the Election, Silly -
06/15/16 08:16 AMCellectar's stock soars after positive results of a study of its tumor treatment -
06/14/16 06:56 PMIBB & XBI: Should You Short the Biotech Industry?
06/13/16 08:06 AMHow Are XBI’s Holdings’ Moving Averages Trending? -
06/11/16 10:17 AMXBI Remained Stable as the Markets Rallied on Higher Oil Prices
06/10/16 07:48 PMSage Therapeutics: SAGE-217's Phase 1 Clinical Trial's Positive Results - Market Realist
06/10/16 07:48 PMAgios Stock Rises on Higher Trading Volumes on June 8 - Market Realist
06/10/16 07:48 PMUS Unemployment Below Forecasts, but Is It Enough to Warrant A Hike? - Market Realist
06/10/16 07:48 PMDownside Ahead For Biotech Stocks? - Benzinga
06/10/16 10:28 AMXBI Remained Stable as the Markets Rallied on Higher Oil Prices - Market Realist
06/09/16 07:58 PMMorgan Stanley Downgrades AbbVie: Stock Down by 2% - Market Realist
06/09/16 10:30 AMUnderstanding Incyte's Revenue Stream in 1Q16 - Market Realist
06/08/16 07:58 PMWhat Helped Incyte Report Growth in 1Q16? - Market Realist
06/07/16 07:40 PMYellen Was Less Dovish than Expected: Will Dollar Stay Strong for Now? - Market Realist
06/07/16 11:44 AMYellen Upbeat on Economy: Wining Sector ETFs -
06/06/16 07:32 PMHumana Rose on Aetna's $13 Billion Bond Sale - Market Realist
06/06/16 07:32 PMUnemployment Falls to 8-Year Low as People Leave the Workforce - Market Realist
06/06/16 07:32 PMNotable ETF Inflow Detected - XBI, ACAD, ANAC, MDVN - Nasdaq
06/06/16 11:40 AMBullish Two Hundred Day Moving Average Cross - KITE - Nasdaq
06/06/16 11:40 AMA Catalyst for Biotech ETFs - Nasdaq
06/03/16 08:07 PMIntercept to Present at Upcoming Investor Conferences - Market Realist
06/03/16 08:07 PMADP Unemployment Change Decent: Initial Jobless Claims Fall - Market Realist
06/03/16 10:28 AMTrying to Believe in Biotech ETFs - ETF Trends
06/03/16 10:22 AMADP Unemployment Change Decent: Initial Jobless Claims Fall -
06/02/16 07:56 PMPRTA Crosses Above Key Moving Average Level - Nasdaq - NasdaqPRTA Crosses Above Key Moving Average LevelNasdaq... with $76.42 as the 52 week high point - that compares with a last trade of $50.00. According to the ETF Finder at ETF Channel, PRTA makes up 1.57% of the SPDR S&P Biotech ETF (Symbol: XBI) which is trading higher by about 2% on the day Thursday.and more »
06/02/16 07:56 PM7 Investments That Usually Soar During the Summer - Money Magazine - Money Magazine7 Investments That Usually Soar During the SummerMoney MagazineThe S&P 500 Food and Beverage Select Industry Index has seen gains in three of the last four years. ... The NASDAQ Biotechnology Index rose about 8% between June and September in 2014, a whopping 25% in 2013, and more than 12% in 2012. ... You can ...
06/02/16 07:56 PMBioMarin Withdraws Application for Kyndrisa: Stock Falls 2.5% - Market Realist - Market RealistBioMarin Withdraws Application for Kyndrisa: Stock Falls 2.5%Market RealistAs of June 1, 2016, BioMarin Pharmaceutical (BMRN) was the most underperforming stock among the large-cap stocks of the SPDR S&P Biotech ETF (XBI). BMRN fell 2.5% and underperformed the SPDR S&P 500 ETF (SPY). The fall came after BioMarin ...and more »
06/02/16 10:43 AMFinally A Biotech ETF Bounce? - Yahoo News - Finally A Biotech ETF Bounce?Yahoo NewsIn recent weeks, IBB, the largest biotech ETF, has been scuffling. The same can be said of rivals, such as the SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotechnology Index Fund (FBT) . There is some encouragement at the fundamental ...
06/02/16 10:43 AMBiotech Stocks: Don't Expect a 'Miraculous Recovery' - Barron's (blog) - Biotech Stocks: Don't Expect a 'Miraculous Recovery'Barron's (blog)The iShares Nasdaq Biotechnology ETF (IBB) has gained 0.6% to $282.90 at 10:10 a.m. today, while the SPDR S&P Biotech ETF (XBI) has gained 1.1% to $58.79. Gilead Sciences has dipped 0.3% to $86.35, Biogen has advanced 0.5% to $288.19, and ...
06/02/16 09:23 AMBiotech Stocks: Don't Expect a 'Miraculous Recovery' -
06/01/16 08:08 PMRegeneron: Coming Into Its Own - Barron's (blog) - Regeneron: Coming Into Its OwnBarron's (blog)... and as a result its earnings and cash flow conversion from revenue lags peers in the industry. Shares of Regeneron Pharmaceuticals have gained 2% to $406.80 at 1:32 p.m. today, nearly triple the SPDR S&P Biotech ETF's (XBI) 0.7% advance to $58.39.and more »
06/01/16 05:07 PMInside Ionis’s Key Pipeline Drug IONIS-TTR -
05/31/16 07:48 PMWhat Happened to Ionis's Revenues in 1Q16? - Market Realist - What Happened to Ionis's Revenues in 1Q16?Market RealistTo divest risk, investors may consider ETFs like the SPDR S&P Biotech ETF (XBI), which has ~1.2% of its total assets in Ionis. XBI also holds 2.7% of its total assets in Acadia Pharmaceuticals (ACAD), 2.3% in Medivation (MDVN), and 2.0% in Ligand ...and more »
05/31/16 07:48 PMAnthem Moves Closer to Cigna Deal - Market Realist - Market RealistAnthem Moves Closer to Cigna DealMarket RealistFor the week ending May 27, 2016, the large-cap stocks within the SPDR S&P Biotech ETF (XBI) outperformed the large-cap stocks of the other biotech (biotechnology) ETFs and the SPDR S&P 500 ETF (SPY) with a return of 5.0%. The large-cap stocks of the ...
05/31/16 07:48 PMA Lesson in Biotech Risk - Barron's (blog) - A Lesson in Biotech RiskBarron's (blog)Shares of StemCells have dropped 83% to $0.53 at 3:06 p.m. today, but its failure has had little impact on biotech stocks in general. The SPDR S&P Biotech ETF (XBI) has gained 1.6% to $57.77, while the iShares Nasdaq Biotechnology ETF (IBB) has risen ...and more »
05/29/16 01:38 AMIntercept Pharmaceuticals (ICPT) – BIDDING PADDLES READY - ValueWalk - ValueWalkIntercept Pharmaceuticals (ICPT) – BIDDING PADDLES READYValueWalkIntercept Pharmaceuticals (ICPT) – BIDDING PADDLES READY by Caleb Gibbons, CFA, FRM,– Originally at IBankCoin. Reposted with permission. Intercept Pharmaceuticals, Inc., waiting until almost midnight, the Friday before the Memorial Day long ...and more »
05/28/16 03:26 PMDelayed FDA Decision Sends Sarepta Therapeutics Soaring - Market Realist - Market RealistDelayed FDA Decision Sends Sarepta Therapeutics SoaringMarket RealistThe Market continued from where it had left off on the previous day, rising further on May 25, 2016. The Dow Jones Industrial Average rose by 0.8%, while the SPDR S&P 500 ETF (SPY) rose by 0.7% on the day. Financial stocks and technology stocks led the ...and more »
About SPDR S&P Biotech

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

Industry, Sector and Symbol:
  • Sector: Financial Services
  • Industry: Exchange Traded Fund
  • Sub-Industry: N/A
  • Exchange: NYSEARCA
  • Symbol: XBI
  • CUSIP:
Key Metrics:
  • Previous Close: $51.85
  • 50 Day Moving Average: $54.67
  • 200 Day Moving Average: $55.03
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Current Quarter EPS Consensus Estimate: $N/A EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha